What happened
The FDA approved Bayer’s Lynkuet for moderate to severe vasomotor symptoms due to menopause. The agency’s trial snapshot describes evidence from OASIS-1, OASIS-2 and OASIS-3, involving 1,423 participants across 21 countries.
Why it matters
A treatment with a different mechanism can expand options for people who cannot or prefer not to use hormone therapy. Approval does not make it the right choice for every patient; benefits, risks, interactions and cost still need individualized discussion.
What to watch
Real-world safety, prescribing guidance, access and coverage, head-to-head evidence, discontinuation rates and representation in post-market data.
